We support life sciences companies and their investors throughout the full transaction lifecycle. On the financing side, this includes advising on convertible loans, seed and series funding rounds, venture capital negotiations, and spin-out structures from universities and knowledge institutes. On the M&A side, we guide you through exit transactions, whether structured as a share deal or an asset deal, from term sheet to closing. That means conducting regulatory and legal due diligence, advising on deal structure, negotiating transaction documents, and addressing sector-specific risks such as IP exposure, regulatory approval status, and compliance obligations under frameworks including the Medical Device Regulation (MDR), In Vitro Diagnostics Regulation (IVDR), Medicines Act, GDPR, the Dutch Vifo Act (for national security screening of investments and mergers), and the healthcare-specific merger review by the Dutch Healthcare Authority (NZa). A particular area of focus is the drafting of sector-specific milestones, whether for tranche payments in financing arrangements or for earn-out and deferred consideration mechanisms in exit transactions, ensuring that regulatory, clinical, and commercial benchmarks are defined with the precision needed to avoid disputes down the line. Attracting and retaining key talent is equally important, which is why we also design and implement employee incentive schemes tailored to your company’s stage and ambitions.
